IDT Australia (ASX: IDT) — Company Overview, News & Financial Data
IDT Australia is a contract development and manufacturing organization providing end-to-end pharmaceutical manufacturing solutions across pre-clinical, clinical, and commercial stages.
IDT Australia
IDT Australia is a contract development and manufacturing organization providing end-to-end pharmaceutical manufacturing solutions across pre-clinical, clinical, and commercial stages. Headquartered in Boronia, Victoria, the company specializes in active pharmaceutical ingredients, including high-potency and cytotoxic compounds, specialty oral dosage forms, advanced sterile fill and finish, lyophilisation, and radiopharmaceuticals. IDT Australia serves global pharmaceutical and biotechnology partners by offering integrated research and development, analytical and microbiology testing, stability testing, regulatory support, secondary packaging, clinical labeling, and supply chain management services under international current Good Manufacturing Practice standards.
Snapshot
Operations
Products and/or services of IDT Australia
- Active Pharmaceutical Ingredients: Development and manufacturing of small molecule active pharmaceutical ingredients from pre-clinical to commercial scale, including specialized handling of highly potent and cytotoxic compounds as well as linker payload manufacturing for antibody drug conjugates.
- Specialty Orals: Formulation, process development, and commercial production of solid oral dosage forms including tablets and capsules, non-sterile liquid pharmaceutical products, and controlled substance preparations covering Schedule 8 and Schedule 9 drug products.
- Sterile Fill and Finish: Aseptic liquid filling and finish manufacturing for sterile injectables into vials, complemented by industrial lyophilisation services under strict cGMP requirements to support clinical trial supply and commercial pharmaceutical production.
- Radiopharmaceuticals: Contract development and manufacturing capabilities for radiopharmaceutical products, supporting nuclear medicine industry partners from initial formulation research and radio labeling through to cGMP batch production and clinical trial supply distribution.
- Analytical and Stability Testing: Comprehensive laboratory services including microbiology testing, analytical method development and validation, raw material clearance, finished product testing, and ICH compliant stability testing programs for regulatory submissions globally.
- Regulatory and Supply Chain Services: Integrated technical support encompassing pharmaceutical research and development, regulatory filing assistance, project management, secondary packaging and clinical labeling, and global logistics and supply chain management.
IDT Australia executive team
- Mark Anthony SimariExecutive Chairman & CEO
- N. R. Malika PereraHead of Finance
- Jim SosicChief Operating Officer
- Paula CouttsHead of People & Safety
- Michael B. ThompsonDirector of Commercial & Business Development
- Robert CaunceDirector of Quality
- Mark Andrew Licciardo B BusCompany Secretary
Latest news about IDT Australia
Recent announcements
What IDT Australia (IDT) has told the market, newest first.
- Change in substantial holding
- Cleansing Notice
- Application for quotation of securities - IDT
Dividend history
Dividends per share paid by IDT Australia, by financial year.
| Financial year | Interim | Final | Special | Total |
|---|---|---|---|---|
| FY2027(to date) | — | — | — | $0.0700 |
| FY2026 | — | — | — | $0.2600 |
| FY2025 | — | — | — | $0.2200 |
| FY2024 | — | — | — | $0.1000 |
| FY2018 | — | — | — | $0.4874 |
Key financials
Reported results for IDT Australia, in AUD.
- Market cap
- 17.2M
- Revenue (TTM)
- 20.4M
- P/E ratio
- —
- EPS (diluted, TTM)
- -0.0
- Dividend yield
- —
- Profit margin
- -13.3%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 20.4M | -1.6M | -2.7M | |
| 19.8M | -6.3M | -8.1M | |
| 13.2M | -6.9M | -5.4M | |
| 6.9M | -8M | -8.5M |